Alexion Pharmaceuticals Inc (ALXN) Gross Profit Margin starting from the first quarter 2021 to first quarter 2020, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Alexion Pharmaceuticals Inc   (NASDAQ: ALXN)


Alexion Pharmaceuticals Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALXN Gross Profit Margin (Mar 31 2021)
Q1 		(Dec 31 2020)
Q4 		(Sep 30 2020)
Q3 		(Jun 30 2020)
Q2 		(Mar 31 2020)
Q1
Y / Y Revenue Change 13.27 %
Seq. Revenue Change 2.81 %
Revenue In Millions $1,636.50
Gross Profit Margin 92.34 %
Gross Profit Margin Total Ranking # 235
Gross Profit In Millions $1,511.10
Y / Y Gross Profit Change 13.35 %
Seq. Gross Profit Change 4.97 %


Commenting First Quarter 2021 Gross Profit Margin
Alexion Pharmaceuticals Inc Gross Profit grew by 4.97 % in Q1 sequentially to 1,511 millions, while Revenue increased by 2.81 %, this led to improvement in the company's Gross Profit Margin to 92.34 %, above the Alexion Pharmaceuticals Inc average Gross Profit Margin.


Observing first quarter 2021 results within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 235, from total ranking in the previous quarter at 246.
Learn about Gross Margin
ALXN's Gross Profit Margin first quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 45
Overall # 226

Gross Profit Margin Statistics
High Average Low
94.19 % 90.43 % 81.72 %
(March 31, 2014)   (Sep 30 2017)


ALXN Gross Income Trends • More of ALXN's Profitabilty Ratios • ALXN Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ALXN's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ALXN's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ALXN's Competitors
Gross Profit Margin Profit Margin for Alexion Pharmaceuticals Inc 's Suppliers
Gross Profit Margin Profit Margin for ALXN's Customers

You may also want to know
ALXN's Annual Growth Rates ALXN's Profitability Ratios ALXN's Asset Turnover Ratio ALXN's Dividend Growth
ALXN's Roe ALXN's Valuation Ratios ALXN's Financial Strength Ratios ALXN's Gross Profit Growth
ALXN's Roa ALXN's Inventory Turnover Ratio ALXN's Growth Rates ALXN's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2021, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2021 MRQ Gross ProfitMar 31 2021 MRQ Revenue
Vistagen Therapeutics Inc   99.98 %$ 0.442  Millions$ 0.442  Millions
Macrogenics Inc   99.90 %$ 16.864  Millions$ 16.881  Millions
Karyopharm Therapeutics Inc   99.65 %$ 23.178  Millions$ 23.260  Millions
Rigel Pharmaceuticals Inc  99.61 %$ 80.702  Millions$ 81.018  Millions
Deciphera Pharmaceuticals Inc   99.12 %$ 24.934  Millions$ 25.156  Millions
Intercept Pharmaceuticals inc   99.01 %$ 80.851  Millions$ 81.661  Millions
Ptc Therapeutics inc   98.81 %$ 116.542  Millions$ 117.942  Millions
Myovant Sciences Ltd   98.78 %$ 24.304  Millions$ 24.605  Millions
Omeros Corporation  98.75 %$ 20.798  Millions$ 21.061  Millions
Global Blood Therapeutics Inc.  98.50 %$ 38.459  Millions$ 39.043  Millions
Corcept Therapeutics Inc  98.40 %$ 78.169  Millions$ 79.437  Millions
Y mabs Therapeutics inc   98.27 %$ 5.290  Millions$ 5.383  Millions
Sellas Life Sciences Group Inc   98.19 %$ 5.440  Millions$ 5.540  Millions
Adamas Pharmaceuticals Inc  98.01 %$ 18.926  Millions$ 19.311  Millions
Acadia Pharmaceuticals Inc   97.95 %$ 104.369  Millions$ 106.554  Millions
Ionis Pharmaceuticals Inc   97.69 %$ 109.029  Millions$ 111.607  Millions
Nabriva Therapeutics Plc  97.55 %$ 2.467  Millions$ 2.529  Millions
Travere Therapeutics Inc   96.53 %$ 45.762  Millions$ 47.407  Millions
Chiasma Inc   96.52 %$ 1.857  Millions$ 1.924  Millions
Strongbridge Biopharma plc  95.10 %$ 7.971  Millions$ 8.382  Millions
Zogenix Inc   95.06 %$ 13.008  Millions$ 13.684  Millions
Siga Technologies Inc  94.79 %$ 4.563  Millions$ 4.814  Millions
Ultragenyx Pharmaceutical Inc   94.78 %$ 94.207  Millions$ 99.395  Millions
Aurinia Pharmaceuticals Inc   94.75 %$ 0.866  Millions$ 0.914  Millions
Serina Therapeutics Inc   94.64 %$ 0.053  Millions$ 0.056  Millions
Beone Medicines Ltd   94.61 %$ 573.187  Millions$ 605.872  Millions
Vaxxinity Inc   94.12 %$ 0.016  Millions$ 0.017  Millions
United Therapeutics Corporation  93.93 %$ 356.100  Millions$ 379.100  Millions
Aveo Pharmaceuticals Inc   92.81 %$ 1.782  Millions$ 1.920  Millions
Neximmune Inc   92.81 %$ 2.251  Millions$ 2.425  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.